Prior board memberships have included BioMimetic Therapeutics, Inc., Genta Incorporated, Javelin Pharmaceuticals, Inc., Engelhard Corporation and Summit Bank Corporation, all public companies, and Bionor Immuno AS and BZL Biologics Inc., both ...

(February 2012) 88 3.8.2.4 Financing to Organovo (March 2012) 88 3.8.2.5 Financing to Cytomedix, Inc. (February 2012) 88 3.8.2.6 Financing to Fate Therapeutics, Inc. (May 2011) 88 3.8.2.7 Financing to Cellular Dynamics International, Inc. (April 2011 ...

The combination with BioMimetic Therapeutics will improve competitive advantage. However, dilution is expected to ... Rank #2 (Buy) and are expected to do well. In addition, Conceptus, Inc. ( CPTS ) carries a Zacks Rank #1 (Strong Buy) and warrants a look.

Prior to Locust Walk, Mr. Ehrlich was a Managing Director at InterWest Partners, during which time he served on the boards of KAI Pharmaceuticals (acquired by Amgen) and Biomimetic Therapeutics, Inc. (acquired by Wright Medical Technologies).

By way of example and without implied limitation, such risks and uncertainties include: failure to realize the anticipated financial and other benefits from the acquisition of BioMimetic Therapeutics, Inc. or a delay in realization thereof; failure to ...

Mr. Ludecker most recently served as Vice President of Global Sales and Marketing for BioMimetic Therapeutics, a NASDAQ-listed biotechnology company, specializing in the development and commercialization of products which promote the healing of ...